Pharmaceutical

MELBOURNE, Australia, May 02, 2016 (GLOBE NEWSWIRE) — Gordagen Pharmaceuticals, an Australian private company, today announced positive top-line results of an independent early-phase US clinical study of its nE1-ElitE™ sports dietary supplement targeting muscle soreness and function following eccentric exercise. This study, conducted by a research group from the University of Mount Union, Ohio, sought …

MELBOURNE, Australia, May 02, 2016 (GLOBE NEWSWIRE) — Gordagen Pharmaceuticals, an Australian private company, today announced positive top-line results of an independent early-phase US clinical study of its nE1-ElitE™ sports dietary supplement targeting muscle soreness and function following eccentric exercise.

This study, conducted by a research group from the University of Mount Union, Ohio, sought to confirm Gordagen’s existing positive efficacy evidence of its nE1-ElitE™ formulation for exercise performance and muscle recovery post exercise.  The double-blind, placebo-controlled study showed significant enhancements to recovery from exercise-induced muscle soreness, muscle micro-trauma and weakness.

Top-line results indicate that participants in the supplement group (administered Gordagen’s nE1-ElitE™) reported a lack of whole-body muscular pain compared to a control group (p=0.02) 24 hours after a particularly challenging weight training session involving 25 eccentric repetitions – or “negatives” – at 80% of one-repetition maximum in the bench press, squat, and biceps curl.  This indicates a significant reduction in Delayed Onset Muscle Soreness (DOMS) after exercise.

Those participants receiving nE1-ElitE™ also exhibited a less-pronounced (p=0.05) hanging arm angle (an indicator of swelling and microtrauma) compared to the control group, 24-hours post-eccentric exercise, pointing to enhanced muscle recovery after exercise.

A strong trend (p=0.056) for nE1-ElitETM supplemented participants to perform a Wingate cycle sprint with greater peak power the day after the “damaging” eccentric exercise compared to the control group, is indicative of improved muscle power maintenance – a critical issue in the ability to recover more quickly and train again sooner.

The study involved a 14-day supplementation program, where participants were assigned to a daily intake of 40mg tocotrienol (nE1-ElitE™) or matching placebo tablets.  Participants were collegiate football players and their weight trained peers in the US undergoing off-season training (N=17).  Muscle recovery after exercise was assessed across a number of variables: psychometric (delayed-onset muscle soreness), morphological (muscle swelling and contracture), and performance (cycle ergometer sprints).

“Gordagen is excited to have worked closely with the team led in part by Associate Professor Lonnie Lowery on this study. As a PhD in exercise physiology, and a registered and licensed dietician who has completed a dissertation and corporate work on nutritional affecters of Delayed Onset Muscle Soreness (DOMS), he is the ideal fit to study nE1-EliteTM. His research experience and industry expertise have been invaluable to Gordagen in the development of this product and will enable us to get to market in the US in the very near term,” commented Dr. Glenn Tong, Gordagen’s CEO and Managing Director.

The research also benefited from oversight from Associate Professor Ron Mendel who holds a PhD in exercise physiology, is a Fellow of the International Society of Sports Nutrition (ISSN) and has a long history working in the dietary supplement industry.

Professor Lowery stated “The results from this early-phase study indicate that Gordagen’s nE1-ElitETM reduces muscle soreness after exercise and improves the maintenance of peak muscle power supporting quickened recovery.”

Data analyses of the results are continuing and will be prepared by the investigators for presentation and publication of a research abstract.

“Drs. Lowery and Mendel and their research group are recognized as a center of research excellence in dietary supplements for sports and nutrition. The data strongly complements observations Gordagen has made in our own DOMS and exercise endurance studies, as well as existing data we have collected to date.  This is a key milestone in Gordagen’s product development program,” commented Dr Ric DeGaris, Chief Operating Officer for Gordagen.

Gordagen intends to launch its exciting and unique nE1-ElitETM supplement in the US market in H2 of 2016.

Investor and Media Enquiries:

CompanyAustralia / AsiaUnited States / Europe
Dr Glenn Tong
Managing Director & CEO
Tel: +61 (0) 412 193 350
Paris Brooke
Bt Novo Pty Ltd
Tel: +61 (0) 407 715 574
David Burke
The Ruth Group
O: 646.536.7009
C: 917-618-2651

About Gordagen Pharmaceuticals Pty Ltd
Gordagen is currently developing tocotrienol-based nutraceuticals backed by clinically regulated research, for the muscle soreness, exercise endurance and heart health markets.  It has a diverse prescription pharmaceutical portfolio, covering core indications of cardiovascular disease, diabetes and hypertension.  The Company’s proprietary and patented MELT3™ melt technology is combined with a formulation of tocotrienols.
www.gordagen.com 

MARKETS

Markets
TSX19202.51-55.81
TSXV642.68-9.68
DOW30984.52-453.74
S&P 5003826.77-73.34
NASD11203.59-320.96
ASX6706.00+177.60

COMMODITIES

Commodities
Gold1819.88-3.55
Silver20.82-0.33
Copper3.76-0.01
Palladium1880.49+12.49
Platinum912.73+5.73
Oil111.62+2.05
Heating Oil4.10-0.01
Natural Gas6.51+0.01

DOWNLOAD FREE REPORTS

×